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Somatic	base	editing	to	model	oncogenic	drivers	in	breast	cancer.	
	
Human	cancer	is	a	disease	of	cooperating	genetic	events	that	is	complex	to	model	
in	vivo.	A	new	study	combines	somatic	base	editing	with	a	mouse	model	of	breast	
cancer	demonstrating	the	potential	to	rapidly	investigate	the	function	of	disease	
specific	point	mutations.		Kirsteen	J.	Campbell1*	and	Karen	Blyth1,2	
	1	CRUK	Beatson	Institute,	Bearsden,	Glasgow,	G61	1BD,	UK.	2	Institute	of	Cancer	Sciences,	College	of	Medical,	Veterinary	and	Life	Sciences,	University	of	Glasgow,	Bearsden	Glasgow,	G61	1QH,	UK.		*	Corresponding	author	-Dr	Kirsteen	Campbell	(k.campbell@beatson.gla.ac.uk.)		Today,	a	plethora	of	genetically	engineered	mouse	models	(GEMMs)	exist	that	have	introduced	transgenes,	specific	mutations	and	gene	knockouts	whose	expression	can	be	triggered	in	both	a	spatial	and	time	controlled	manner	1.	These	models	have	contributed	a	vast	amount	to	our	knowledge	of	homeostatic	and	disease	processes,	but	the	establishment	and	maintenance	of	GEMMs	remains	expensive	and	time	consuming.	Furthermore,	the	transmission	of	genetically	altered	alleles	frequently	involves	surplus	generation	of	mice	with	undesired	genotypes.	These	considerations	can	render	GEMMs	impractical	for	budget	and	time-constrained	projects.			For	a	number	of	years	the	Jonkers’	lab	have	been	leading	the	way	in	developing	and	refining	mouse	models	of	breast	cancer	to	recapitulate	the	human	disease.	One	such	approach	models	BRCA1	mutant	breast	cancer	whereby	conditional	loss	of	Brca1	and	Trp53	is	driven	specifically	in	the	mammary	epithelium	by	virtue	of	the	whey	acid	protein	Cre	recombinase	(WapCre).	In	this	genetic	context	female	mice	develop	mammary	tumours	with	median	survival	of	198	days	(range~100-260	days)2.	These	tumours	represent	the	triple	negative	breast	cancer	subtype	as	they	lack	expression	of	estrogen,	progesterone	and	human	epidermal	growth	factor	receptors	(ER,	PR,	HER2).	The	co-operative	impact	of	MYC-overexpression	in	this	model	was	elegantly	demonstrated	through	addition	of	a	germline	MYC	transgene	that	significantly	accelerated	disease	onset2.		Importantly,	this	MYC-	driven	acceleration	of	Brca1;Trp53	disease	could	also	be	achieved	using	somatic	delivery	of	a	lentivirus	encoding	MYC	directly	into	the	mammary	gland	by	intraductal	injection2	(Fig	1A).	Having	already	shown	that	intraductal	delivery	of	small	guide	RNAs	(sgRNAs)	could	effectively	target	germline	encoded	Cas9	nucleases	to	tumour	suppressors	such	as	Pten	(Fig	1B),	this	somatic	approach	was	used	to	introduce	coincident	MYC	overexpression	and	PTEN	loss	(Fig	1C),	which	decreased	latency	of	mammary	tumorigenesis	even	further	2,3.		This	methodology	allowed	the	study	of	simultaneous	somatic	over-expression/loss	of	function	specifically	in	the	injected	mammary	gland,	and	in	the	context	of	pre-defined	genetically	engineered	alleles.	This	work	marked	a	technological	advance	in	line	with	the	3R’s	approach	but	also	reduced	cost	and	time.			
Whilst	breast	cancer	is	thought	to	be	largely	a	disease	of	copy	number	alteration,	pathogenic	point	mutations	have	also	been	identified	as	drivers	of	the	disease	4,5.	Robust	methods	for	studying	the	function	of	point	mutations	in	mice	include	knock-in	expression	of	mutant	genes,	which	again	entails	significant	cost	and	time.	To	circumvent	this,	and	building	on	their	previous	work,	Jonkers	and	colleagues	have	taken	advantage	of	recently	developed	base	editing	enzymes	to	streamline	the	introduction	of	a	range	of	somatic	point	mutations	in	situ	6.		This	involved	generating	a	new	transgenic	mouse	engineered	to	express	a	cytosine	base	editor,	BE3	(developed	by	the	Liu	lab	7)	in	response	to	activation	with	Cre-recombinase	6.	BE3	is	a	hybrid	protein	composed	of	Streptococcis	pyogenes	Cas9	nickase	(SpCas9D10A)	fused	with	rat	APOBEC1	cytosine	deaminase	and	a	uracil	glycosylase	inhibitor	domain	that	can	introduce	targeted	C-T	base	mutations	when	guided	to	genomic	loci	by	specific	sgRNAs	7.	This	transgene	was	inserted	into	the	Col1a	locus	of	WapCre	Brca1fl/fl;Trp53fl/fl	ES	cells	using	a	GEMM-ESC	approach	8	where	the	resultant	mice	have	concomitant	BE3	expression	along	with	loss	of	BRCA1	and	p53	in	the	mammary	epithelium6.			To	test	the	ability	of	BE3	to	introduce	nucleoside	substitutions	in	situ,	the	authors	focussed	on	the	PI3-kinase/Akt	pathway	(normally	antagonised	by	PTEN),	which	is	frequently	altered	in	breast	cancer	9	.	Through	this	transgenic	BE3	system	oncogenic	E17K	missense	mutations	in	AKT1	(Fig	1D)	or	missense	mutations	in	PIK3CA	(the	catalytic	subunit	of	PI3K),	such	as	the	hotspot	mutations	E542K	and	E545K	(and	the	rarer	E452K	mutation),	were	introduced	somatically	by	sgRNA	intraductal	delivery	and	all	reduced	the	latency	of	WapCre	
Brca1fl/fl;Trp53fl/fl	Lenti-Myc	tumour	development.	Target	C-to-T	conversion	rates	were	~60-80%	in	end-stage	tumours	and	analysis	by	immunohistochemistry,	western	blot	and	RNA	sequencing	showed	alteration	in	downstream	pathways	as	expected	by	interference	with	AKT1/PI3K.	Delivery	of	a	Lentivirus	encoding	tandem	Pik3ca	and	Trp53	targeting	sgRNA	allowed	editing	at	both	loci	and	demonstrates	the	potential	to	rapidly	model	multiple	co-operative	events	in	situ.	Importantly,	as	a	control	for	off-target	effects,	introduction	of	a	non-inactivating	PIK3CA	mutation	-	that	should	have	neutral	effect	on	PI3K	activity	-	did	not	alter	tumour	latency.	Presumably	this	is	because	this	mutation	provides	no	selective	advantage	and	therefore	this	would	be	less	well	represented	in	the	end	stage	tumour.																														In	theory,	the	modified	Cas9	used	here	with	nickase	activity	should	avoid	introduction	of	double	strand	breaks	that	can	lead	to	indels	and	translocations.	However,	whilst	attempting	bi-allelic	targeting	of	an	sgPtenQ245	nonsense	mutation	the	authors	noted	that	indels	were	occurring	and	that	PtenQ245	base	edits	never	occurred	at	both	alleles,	instead	either	this	edit	was	observed	at	one	allele	and	a	frame-shift	indel	at	the	other	allele,	or	both	alleles	had	the	indel	6.	To	probe	this	further	they	addressed	the	impact	of	targeting	a	premature	stop	codon	into	the	Trp53	tumour	suppressor	gene	in	a	context	of	Trp53	heterozygosity.	This	revealed	that	when	point	mutations	were	targeted	to	tumour	suppressors	such	as	Pten	or	Trp53,	unintended	insertions	and	deletions	at	the	targeted	loci	were	actually	selected	for	in	this	tumorigenic	context.	Other	unintended	mutations	also	occurred:	bystander	edits	at	local	cytosines	were	
frequent	in	all	models	tested	but	in	most	cases	this	did	not	introduce	a	change	in	amino	acid	sequence.	Furthermore,	these	bystander	edits	were	not	exclusively	C-T	with	C-A	and	rarer	C-G	also	being	observed	6.			Although	whole	genome	sequencing	in	3T3	cells	did	not	show	potential	pathogenic	off-target	effects	of	BE3	in	the	Annunziato	study,	BE3	editing	at	distal	locations	has	been	characterised	in	other	systems	and	can	occur	in	proto-oncogenes	and	tumour	suppressors	10,11.	Whole	genome	sequencing	is	required	to	detect	distant	mutations	and	is	a	low-throughput	process	in	heterogenous	cell	populations.	Concerns	about	off-target	effects	are	less	relevant	when	modelling	co-operative	oncogenesis	in	the	triple	negative	breast	cancer	model	as	
Brca1/Trp53	null	tumours	have	defective	DNA	repair	pathways	with	heavily	mutated	heterogenous	genomes	2.	However,	the	prominence	of	unexpected	indels	when	targeting	tumour	suppressors,	such	as	PTEN	and	p53,	in	this	study	shows	that	unintended	alterations	that	favour	tumour	development	will	be	strongly	selected	for.		It	is	possible	that	new	oncogenic	players	relevant	to	triple	negative	breast	cancer	could	be	identified	by	enrichment	for	off-target	editing	in	this	model.					Progression	in	the	field	of	base-editing	is	rampant,	in	the	time	it	has	taken	to	make	the	BE3	transgenic	mouse	and	perform	these	studies	further	generations	of	base	editors	have	been	engineered	that	have	fewer	off	target	effects	and	also	allow	A-G	conversion	12,13.	The	work	by	Annunziato	et	al.,	paves	the	way	for	incorporation	of	these	newer	base	editors	into	in	situ	models	of	tumorigenesis.	Furthermore,	recently	developed	search	and	replace	genome	editing	systems	could	also	be	developed	for	in	situ	use	in	GEMMs	14	.	Similarly,	as	future	generations	of	RNA	base	editors	that	alter	amino	acid	sequence	without	genome	alteration	are	developed	15,	precise,	flexible	and	reversible	modification	may	be	achieved	in	pipelines	based	on	the	Jonkers	format.	This	methodology	is	scalable	and	adaptable	to	many	cell	and	tumour	types	through	use	of	alternative	Cre,	GEMMs	and	sgRNA	delivery	method	or	site	(Fig	1E).	The	advantage	of	orthotopic	delivery	into	the	mammary	gland	elegantly	facilitates	these	approaches	to	model	breast	cancer;	but	it	is	exciting	that	with	the	advent	of	increased	orthotopic	delivery	systems	(eg	colon	16)	this	should	permit	the	wider	application	of	base	editing	in	modelling	other	tumour	types.				References		1.	Blyth	K,	Morton	JP	&	Sansom	OJ.	Curr	Opin	Genet	Dev.	22,	28-35	(2012).	2.	Annunziato	S.	et	al.	Nat	Commun.		10,	397	(2019).		3.	Annunziato	S.	et	al.	Genes	Dev.	30,	1470-1480	(2016).	4.	Zack	TI.	et	al.	Nat	Genet.	45,	1134-1140	(2013).	5.	Nik-Zainal	S.	et	al.	Nature	534,	47-54	(2016).	6.	Annunziato	S.	et	al.	EMBO	J.	e102169	(2020).	7.	Komor	AC,	Kim	YB,	Packer	MS,	Zuris	JA,	&	Liu	DR.	Nature	533,	420-424	(2016).	8.	Huijbers	IJ.	et	al.	EMBO	Mol	Med.	6,	212-225	(2014).	
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	Fig.	1	|	An	expanding	toolbox	for	modeling	genetic	aberrations	in	breast	
cancer.	Schematic	showing	recent	developments	that	combine	germline	encoded	alterations	in	genetically	engineered	mouse	models	(GEMMs)	with	somatically	altered	genetics	via	mammary	intraductal	delivery	of	lentiviral	vectors.	This	work	creates	a	platform	for	future	developments	encompassing	new	types	of	nucleic	acid	editors	and	can	be	adapted	for	use	in	a	variety	of	GEMMs	to	rapidly	model	the	function	of	a	range	of	genetic	alterations	in	cancer.	Future	developments	could	include	new	cytosine	base	editor	variants;	adenine	base	editors;	search-and-replace	editing;	RNA	base	editors;	other	cell	type-specific	Cre;	inducible	Cre;	GEM	that	model	other	tumor	types;	and	alternate	delivery	sites/systems.			
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